Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

@article{Scher1997BicalutamideFA,
  title={Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.},
  author={Howard I. Scher and Christine Liebertz and William Kevin Kelly and Madhu Mazumdar and Christopher H R Brett and Lawrence Schwartz and G Kolvenbag and L. N. Shapiro and Michael C Schwartz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 8},
  pages={2928-38}
}
PURPOSE To determine the therapeutic effects of bicalutamide 200 mg in patients with prostate cancers of different hormone sensitivities. METHODS Patients with progressive prostate cancer were treated with bicalutamide 200 mg daily. Before treatment, patients' tumors were classified on the basis of prior hormone exposure and by serum testosterone levels into androgen-dependent and androgen-independent groups. Prior exposure to flutamide and response to flutamide withdrawal was also considered… CONTINUE READING